Trial meets its main goal
The late-stage trial compared RYZ101 with standard-of-care treatments in patients with GEP-NETs whose disease had progressed after lutetium-177-based therapy. GEP-NETs are rare cancers that arise in the hormone-producing cells of the gastrointestinal tract and pancreas.
Bristol Myers said the drug’s safety profile was consistent with previous studies. Patients will continue treatment and be followed for overall survival. The key points are:
A significant delay in disease progression compared with standard treatment.
A safety profile consistent with earlier data.
Detailed data to be presented at a future medical meeting.
A “cannonball” aimed at the tumour
RYZ101 belongs to the class of radiopharmaceuticals, a therapy closely watched by investors, which works by attaching a radioactive isotope to a targeting molecule, delivering radiation directly to cancerous tissue or tumour-associated cells while limiting damage to healthy tissue. The drug is also being studied in early-stage trials in hormone receptor-positive metastatic breast cancer.

















